Biology of Blood and Marrow Transplantation

A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma..  26:2223-2228. 2020

Use of Potentially Inappropriate Medications in Older Allogeneic Hematopoietic Cell Transplantation Recipients.  26:2329-2334. 2020

Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.  26:1784-1802. 2020

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.  26:e247-e255. 2020

Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.  26:1394-1401. 2020

Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.  26:798-804. 2020

Phase II Clinical Trial Evaluating the Standardization of CD3+ T-Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants (PBSCT) from Matched Related Donors.  26:s178. 2020

Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy 2020

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.  26:e7-e15. 2020

Hematopoietic Cell Transplant–Related Toxicities and Mortality in Frail Recipients.  25:2454-2460. 2019

Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study.  25:2261-2266. 2019

Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.  25:1875-1883. 2019

Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.  25:1744-1755. 2019

Late Mortality after Allogeneic Bone Marrow Transplantation in Childhood for Bone Marrow Failure Syndromes and Severe Aplastic Anemia.  25:749-755. 2019

Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.  25:515-521. 2019

The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma.  25:e73-e75. 2019

Late Mortality after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2).  25:328-334. 2019

Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications.  25:233-238. 2019

Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.  25:73-85. 2019

Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.  24:1554-1562. 2018

Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.  24:1379-1385. 2018

Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation.  24:909-913. 2018

Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors.  23:700-705. 2017

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.  23:367-378. 2017

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.  23:269-277. 2017

Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the Australasian Bone Marrow Transplant Recipient Registry.  23:147-152. 2017

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.  23:10-23. 2017

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.  22:1543-1551. 2016

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.  22:1197-1205. 2016

Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.  22:782-795. 2016

Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum.  22:564-570. 2016

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.  21:1746-1753. 2015

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.  21:1155-1166. 2015

Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: Results of a dose de-escalation trial.  21:900-905. 2015

Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?.  21:713-719. 2015

Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.  21:701-706. 2015

Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation.  21:552-558. 2015

Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy.  21:559-564. 2015

Cytomegalovirus (CMV) Infection in Autologous Stem Cell Transplant (ASCT) Recipients in the Era of Rituximab (R) Use.  21:s139. 2015

Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.  20:1975-1981. 2014

Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stemcell transplantation.  20:1767-1771. 2014

Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation.  20:1729-1736. 2014

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations.  20:295-308. 2014

Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: Implications for risk-stratification.  20:222-228. 2014

Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.  20:402-408.e1. 2014

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma.  20:951-959. 2014

Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the american society for blood and marrow transplantation.  20:1262-1273. 2014

Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia.  20:1224-1228. 2014

Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research.  20:89-97. 2014

Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.  20:581-586. 2014

Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.  19:1615-1624. 2013

Burden of Morbidity in 10+ Year Survivors of Hematopoietic Cell Transplantation: Report from the Bone Marrow Transplantation Survivor Study.  19:1073-1080. 2013

Allogeneic th1 cells home to host bone marrow and spleen and mediate ifnγ-dependent aplasia.  19:876-887. 2013

Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research.  19:173-179. 2013

Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.  19:260-265. 2013

National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines.  18:334-347. 2012

Subsequent Malignant Neoplasms after Hematopoietic Cell Transplantation.  18. 2012

NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Etiology and Pathogenesis of Late Effects after HCT Performed in Childhood-Methodologic Challenges.  17:1428-1435. 2011

NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: State of the Science, Future Directions.  17:1424-1427. 2011

Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus-Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.  17:1176-1181. 2011

Predictors of Late Cardiovascular Complications in Survivors of Hematopoietic Cell Transplantation.  16:1138-1144. 2010

Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation—An Increasingly Recognized Manifestation of Chronic Graft-versus-Host Disease.  16:S106-S114. 2010

Long-Term Consequences of Hematopoietic Stem Cell Transplantation: Current State of the Science.  16. 2010

Late Effects in Survivors of Hodgkin and Non-Hodgkin Lymphoma Treated with Autologous Hematopoietic Cell Transplantation: A Report from the Bone Marrow Transplant Survivor Study.  13:1153-1159. 2007

Second Malignancies after Allogeneic Hematopoietic Cell Transplantation.  13:1121-1134. 2007

Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen.  12:770-777. 2006

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.  11:307-313. 2005

γδ T cells: A new frontier for immunotherapy?.  11:161-168. 2005

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.  9:649-656. 2003

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed..  9:649-656. 2003

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome.  9:766-771. 2003

A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.  8:619-624. 2002

Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimen.  8:453-461. 2002

Effects of Allogeneic Bone Marrow Transplantation on Recipient Bone Mineral Density: A Prospective Study.  6:344-351. 2000

Effects of allogeneic bone marrow transplantation on recipient bone mineral density: A prospective study..  6:344-351. 2000

High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission.  5:292-298. 1999

Stable transduction of recombinant adeno-associated virus into hematopoietic stem cells from normal and sickle cell patients..  2:24-30. 1996

Stable transduction of recombinant adeno-associated virus into hematopoietic stem cells from normal and sickle cell patients.  2:24-30. 1996